Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2677 of 3330
Next
>>
>
66901 to 66925 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7492.069	0.7649	0.7141	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7492.069	0.7058	0.6365	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7492.069	0.6168	0.5144	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7492.069	0.5945	0.4826	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7492.069	0.5791	0.4604	1.7373
MCF7	HR+	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7492.069	0.4916	0.3290	1.7373
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7494.068	1.0175	1.0381	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7494.068	0.8298	0.6323	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7494.068	0.7431	0.4475	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7494.068	0.6135	0.1750	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7494.068	0.6094	0.1663	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7494.068	0.6195	0.1874	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7494.068	0.6264	0.2020	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7494.068	0.5950	0.1365	0.9185
MDA-MB-134-VI	HR+	Luminal	Sirolimus	MTOR	MTOR	167	uM	7494.068	0.5857	0.1172	0.9185
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.0000853	uM	7495.069	1.7513	5.0159	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.000427	uM	7495.069	0.9575	0.8365	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.00213	uM	7495.069	1.6549	4.3822	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.0107	uM	7495.069	0.8794	0.5535	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.0533	uM	7495.069	1.5095	3.4923	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.267	uM	7495.069	1.3534	2.6251	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	1.33	uM	7495.069	1.1426	1.5988	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	6.67	uM	7495.069	1.2379	2.0422	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	33.3	uM	7495.069	1.4344	3.0639	0.5089
MDA-MB-157	TNBC	Basal B	Sirolimus	MTOR	MTOR	0.000427	uM	7879.068	1.0117	1.0127	1.8348

|<
<<
Previous
Page 2677 of 3330
Next
>>
>
66901 to 66925 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)